Mednet Logo
HomeQuestion

Are there best practices for managing or mitigating toxicity from sotorasib such as hyperbilirubinemia or edema?

3 Answers
Mednet Member
Mednet Member
Medical Oncology · UCI Health

Personally, I think it is important to monitor closely so that any adverse events could be detected early and acted upon quickly. Based on the package insert of sotorasib (lumakras_pi_hcp_english.pdf), liver function tests should be monitored every 3 weeks for the first 3 months of treatment then on...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Roswell Park Comprehensive Cancer Center

While hyperbilirubinemia and edema are generally uncommon, hepatotoxicity is more often manifested as liver enzyme elevation. Patient education on signs/symptoms (e.g. nausea, vomiting, anorexia) and close monitoring are key steps to mitigate toxicity and enable dose interruption early, with subsequ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University/Sidney Kimmel Cancer Center

I haven't had either of these toxicities on single agent sotorasib. The main toxicity I see in my clinic is diarrhea and abdominal pain, which can be difficult to treat. We have found that early initiation of anti-diarrheals such as imodium and lomotil is important. For many patients, it seems that ...

Register or Sign In to see full answer